This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access Fragmin® (dalteparin sodium) prescribing information and adverse event reporting can be found at the bottom of the page.

Fragmin Tolerability

Fragmin has been extensively used since its launch in 19921

Approximately 3% of the patients receiving prophylactic treatment reported side effects2-7. Fragmin is an antithrombotic agent that acts mainly through its ability to potentiate the inhibition of Factor Xa and thrombin by antithrombin. Compared with standard, unfractionated heparin, Fragmin has a reduced adverse effect on platelet function and platelet adhesion, and thus only has a minimal effect on primary haemostasis2-7.

Please refer to the SPC for a list of adverse events which may possibly be associated with Fragmin.

The risk of bleeding is dependent on dose. Most bleedings are mild. Severe bleedings have been reported, some cases with fatal outcome.

Heparin products can cause hypoaldosteronism which may result in an increase in plasma potassium. Rarely, clinically significant hyperkalaemia may occur particularly in patients with chronic renal failure and diabetes mellitus.

Long term treatment with heparain has been associated with a risk of osteoporosis. Although this has not been observed with dalteparin, the risk of osteoporosis cannot be excluded.

Paediatric population: Frequency, type and severity of adverse reactions in children are expected to be the same as in adults. The safety of long term dalteparin administration has not been established2-7.


References
  1. Data on file (IMS Data).
  2. Fragmin SmPC [Surgical Thromboprophylaxis (2,500 IU and 5,000 IU syringes)]. Available at: https://www.medicines.org.uk/emc/product/4246 and https://www.medicines.org.uk/emc/product/4247
  3. Fragmin SmPC [Medical Thromboprophylaxis (5,000 IU syringes)]. Available at: https://www.medicines.org.uk/emc/product/4247
  4. Fragmin SmPC [Treatment of VTE (7,500-18,000 IU syringes, 10,000 IU/1 ml ampoules, 100,000 IU/4 ml Multidose Vial)]. Available at: https://www.medicines.org.uk/emc/search?q=fragmin
  5. Fragmin SmPC [Unstable Angina (Graduated syringe 10,000 IU/ml solution for injection, 10,000 IU/1 ml ampoule, 7,500 IU)]. Available at: https://www.medicines.org.uk/emc/search?q=fragmin
  6. Fragmin SmPC [Haemodialysis/Haemofiltration (10,000 IU/1 ml & 10,000 IU/4 ml ampoules)]. Available at: https://www.medicines.org.uk/emc/product/4251 and https://www.medicines.org.uk/emc/product/4244
  7. Fragmin SmPC [Extended Treatment in Oncology (5,000-18,000 IU syringes)]. Available at: https://www.medicines.org.uk/emc/search?q=fragmin
PP-FRA-GBR-0252. March 2021

Quick links

Categories of Anticoagulants

Find out more

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No